A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Boehringer Ingelheim
Teclison Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Exelixis
Novartis
Orano Med LLC
Amgen
RayzeBio, Inc.
ITM Solucin GmbH
Turning Point Therapeutics, Inc.
Ipsen
RayzeBio, Inc.
Boston Scientific Corporation